SCLERODERMA, SYSTEMIC

This study tested whether tofacitinib, a drug that calms the immune system, works better than methotrexate for reducing skin thickening in people with a severe form of scleroderma. 34 adults with early-stage diffuse scleroderma took part. The main goal was to measure changes in s…

This study tested an experimental oral drug, Avenciguat (BI 685509), in 214 adults with scleroderma (systemic sclerosis) who had lung fibrosis or blood vessel issues. Participants were randomly assigned to take the drug or a placebo three times daily for at least 11 months. The m…

This study looked at how scleroderma, an autoimmune disease, limits hand movement in 30 adults. Researchers measured joint motion and skin tightness in both the dominant and non-dominant hand to see which is more affected. The goal was to better understand hand disability to guid…

This study looked at how certain immune cells (T cells and NK cells) might harm blood vessels in people with systemic sclerosis (scleroderma). Researchers collected blood samples from 30 participants to measure a molecule called Fractalkine and study how these immune cells intera…

This study looked at how B cells, a type of immune cell, might contribute to scarring in people with systemic sclerosis (scleroderma). Researchers compared blood and skin samples from 71 participants, including patients and healthy volunteers. The goal was to understand the disea…